At 3 years of follow-up, unilateral transcranial magnetic resonance-guided focused ultrasound (tcMRgFUS) thalamotomy demonstrates persistent, significant tremor reduction, accompanied by functional and quality of life (QOL) improvements, and a positive safety profile.
Why this matters
A previous randomized controlled trial (RCT) comparing tcMRgFUS thalamotomy to sham demonstrated tremor regression and improvements in disability and QOL that were sustained at 12 months, and a favorable safety profile; a follow-up study confirmed sustained outcomes at 24 months.
Demonstrating continued efficacy and safety after tcMRgFUS will aid patients and clinicians in making treatment decisions.
Want to read more?
Log in or sign up to access all Neurodiem content.
Already have an account? Log In
International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.
No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.